Enjoy complimentary customisation on priority with our Enterprise License!
The non-small cell lung cancer (NSCLC) drugs market size is estimated to grow at a CAGR of 9.25% between 2022 and 2027. The market size is forecast to increase by USD 15,936.89 million. The growth of the market depends on several factors, including the increasing prevalence and incidence of non-small cell lung cancer, the strong drug pipeline and recent drug approvals, and the availability of patient assistance programs.
This non-small cell lung cancer drugs market report extensively covers market segmentation by type (adenocarcinoma, squamous cell carcinoma, and large cell carcinoma), product (biologics, small molecule targeted therapy, and chemotherapy), and geography (North America, Europe, Asia, and Rest of World (ROW)). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.
To learn more about this report, View Report Sample
The increasing prevalence and incidence of non-small cell lung cancer are notably driving the market growth, although factors such as the high cost of non-small cell lung cancer treatment may impede the market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
One of the key factors driving growth in the NSCLC drugs market is the increasing prevalence and incidence of non-small cell lung cancer. Globally, the prevalence of lung cancer has increased due to the rise in risk factors such as cigarette smoking, secondary smoking, air pollution, and occupational exposure. As per the American Cancer Society estimates, in 2021, there were approximately 235,760 new cases of lung cancer in the US, and an estimated 131,880 people were expected to die of this disease.
NSCLC accounted for 84% of the total number of lung cancer cases in the US in 2021. On the other hand, in Asian countries, rapid industrial development and sub-urbanization, and disease patterns are leading to the increased prevalence of non-small cell lung cancer. Such factors will be contributing to the non-small cell lung cancer drugs market growth during the forecast years.
The introduction and approval of combination therapies are one of the key NSCLC drugs market trends fueling the market growth. Combination therapies are being developed due to the increase in drug resistance, which is one of the key non-small cell lung cancer drugs market trends. Combination therapy can reduce drug resistance as tumors are less likely to have resistance to multiple drugs.
In May 2020, Eli Lilly and Company received approval from the US FDA for its CYRAMZA (ramucirumab injection, 10 mg or mL solution), in combination with erlotinib, for the first-line treatment of people with metastatic NSCLC, with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. The introduction and approval of combination therapies are expected to drive market growth during the forecast period.
The high cost of treatment will be a major challenge for the NSCLC drugs market during the forecast period. Non-small cell lung cancer can be treated by surgery, radiation therapy, chemotherapy, targeted therapies, and immunotherapy. The cost of vinorelbine can range from USD 23.62 to USD 29.50 for a supply of 1 milliliter and from USD 45.33 to USD 84 for 5 millimeters. The cost of cisplatin can range from USD 20.69 to USD 25.43 for a supply of 50 milliliters and from USD 69.15 to USD 92.50 for 200 millimeters.
Similarly, immunotherapy for non-small cell lung cancer may include immune checkpoint inhibitors such as OPDIVO, KEYTRUDA, TECENTRIQ, and IMFINZI. The overall cost of treatment, including diagnosis, hospitalization, outpatient office visits, and a monthly initial treatment phase, is USD 46,000 per patient. Hence, such high costs of cancer treatment are expected to negatively impact market growth during the forecast period.
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Non-small Cell Lung Cancer Drugs Market Customer Landscape
Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
AbbVie Inc.: The company offers non-small cell lung cancer drugs such as Telisotuzumab vedotin. The company conducts research and development, manufacturing, commercialization, and sale of innovative medicines and therapies to allocate resources and assess business performance on a global basis in order to achieve established long-term strategic goals.
The research report also includes detailed analyses of the competitive landscape of the market and information about 15 market vendors, including:
Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.
The market share growth by the adenocarcinoma segment will be significant during the forecast period. Adenocarcinoma cancer is formed in the glandular tissue that lines certain internal organs and produces and releases substances such as mucus, digestive juices, and other fluids into the body. Most cancers of the breast, lung, esophagus, stomach, colon, rectum, pancreas, prostate, and uterus are adenocarcinomas.
Get a glance at the market contribution of various segments View the PDF Sample
The adenocarcinoma segment was valued at USD 8,047.94 million in 2017 and continued to grow until 2021. Adenocarcinoma can spread to other parts of the body. This happens when cancer cells break away from the tumor and travel throughout the body through the bloodstream or lymph nodes. This is called invasive adenocarcinoma. The cancer spreads depending on where the abnormal cells started. For example, pancreatic cancer usually spreads to the liver first. Breast cancer usually spreads to the lymph nodes first. Adenocarcinoma can also spread to the lungs, brain, bones, bone marrow, and other organs. Hence, such factors will contribute to the growth of the market in focus during the forecast period.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 37% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. The rising incidence of risk factors such as cigarette smoking, air pollution, and radiation are leading to the high prevalence of non-small cell lung cancer in North America. For instance, according to the CDC, in the US, approximately 200,000 people are diagnosed with lung cancer each year. The high prevalence of non-small cell lung cancer in the region also prompts government organizations to raise awareness through lung cancer screening programs such as National Comprehensive Cancer Control Program (NCCCP) and National Tobacco Control Program.
Several organizations are taking initiatives to fund research in lung cancer. In November 2021, the Lung Cancer Research Foundation (LCRF) and AstraZeneca (AZ) announced five research grant awards totaling USD 900,000, which are focused on understanding epidermal growth factor receptor (EGFR) inhibitor and immunotherapy resistance; each project will receive USD 180,000 over a two-year period.
The outbreak of COVID-19 led to a slight decline in the growth of the non-small cell lung cancer drugs market in North America in Q1 2020, owing to the temporary halt in the research of new drugs for NSCLC treatment and reduced hospital and clinic visits owing to the imposition of stay-at-home orders. However, the resumption of normal industrial and commercial activities and expedited research programs for NSCLC drugs are expected to drive the growth of the non-small cell lung cancer drugs market in the region during the forecast period.
The non-small cell lung cancer drugs market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
Technavio categorizes the global non-small cell lung cancer drugs market as a part of the global pharmaceuticals market within the overall healthcare industry. The parent global pharmaceuticals market covers products and companies engaged in the R&D or production of generic drugs, non-generic drugs, and veterinary drugs. Our market research report has extensively covered external factors influencing the parent market growth during the forecast period.
Non-small Cell Lung Cancer Drugs Market Scope |
|
Report Coverage |
Details |
Page number |
167 |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 9.25% |
Market growth 2023-2027 |
USD 15,936.89 million |
Market structure |
Fragmented |
YoY growth 2022-2023(%) |
8.88 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 37% |
Key countries |
US, Canada, Germany, UK, and China |
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, BeiGene Ltd., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Innovent Biologics Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Merck KGaA, Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc., PharmaMar SA, Regeneron Pharmaceuticals Inc., Sanofi, and Takeda Pharmaceutical Co. Ltd. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Market Segmentation by Product
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.